|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Rosuvastatin#Warnings]] |
| {{Rosuvastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
|
| |
|
| ==Warnings and Precautions==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ===Skeletal Muscle Effects===
| | [[Category: Statins]] |
| | |
| Cases of [[myopathy]] and [[rhabdomyolysis]] with acute [[renal failure]] secondary to [[myoglobinuria]] have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40 mg).
| |
| <div>
| |
| CRESTOR should be prescribed with caution in patients with predisposing factors for [[myopathy]] (e.g., age ≥ 65 years, inadequately treated [[hypothyroidism]], [[renal impairment]]).
| |
| | |
| The risk of [[myopathy]] during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or [[niacin]]), [[gemfibrozil]], [[cyclosporine]], [[lopinavir]]/[[ritonavir]], or [[atazanavir]]/[[ritonavir]] [see Dosage and Administration (2) and Drug Interactions (7)]. Cases of [[myopathy]], including [[rhabdomyolysis]], have been reported with HMG-CoA reductase inhibitors, including rosuvastatin, coadministered with [[colchicine]], and caution should be exercised when prescribing CRESTOR with [[colchicine]] [see Drug Interactions (7.7)].
| |
| | |
| CRESTOR therapy should be discontinued if markedly elevated creatine kinase levels occur or [[myopathy]] is diagnosed or suspected. CRESTOR therapy should also be temporarily withheld in any patient with an acute, serious condition suggestive of [[myopathy]] or predisposing to the development of [[renal failure]] secondary to [[rhabdomyolysis]] (e.g., sepsis, [[hypotension]], [[dehydration]], major surgery, [[trauma]], severe metabolic, endocrine, and electrolyte disorders, or uncontrolled [[seizures]]).
| |
| | |
| There have been rare reports of immune-mediated necrotizing [[myopathy]] (IMNM), an autoimmune [[myopathy]], associated with [[statin]] use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing [[myopathy]] without significant inflammation; improvement with immunosuppressive agents.
| |
| | |
| All patients should be advised to promptly report to their physician unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing CRESTOR.
| |
| | |
| ===Liver Enzyme Abnormalities===
| |
| | |
| It is recommended that liver enzyme tests be performed before the initiation of CRESTOR, and if signs or symptoms of liver injury occur.
| |
| | |
| Increases in serum transaminases [AST (SGOT) or ALT (SGPT)] have been reported with HMG‑CoA reductase inhibitors, including CRESTOR. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. There were two cases of [[jaundice]], for which a relationship to CRESTOR therapy could not be determined, which resolved after discontinuation of therapy. There were no cases of [[liver failure]] or irreversible liver disease in these trials.
| |
| | |
| In a pooled analysis of placebo-controlled trials, increases in serum transaminases to >3 times the upper limit of normal occurred in 1.1% of patients taking CRESTOR versus 0.5% of patients treated with placebo.
| |
| | |
| There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including rosuvastatin. If serious liver injury with clinical symptoms and/or [[hyperbilirubinemia]] or jaundice occurs during treatment with CRESTOR, promptly interrupt therapy. If an alternate etiology is not found, do not restart CRESTOR.
| |
| | |
| CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease [see Clinical Pharmacology (12.3)]. Active liver disease, which may include unexplained persistent transaminase elevations, is a contraindication to the use of CRESTOR [see Contraindications (4)].
| |
| | |
| ===Concomitant Coumarin Anticoagulants===
| |
| | |
| Caution should be exercised when anticoagulants are given in conjunction with CRESTOR because of its potentiation of the effect of coumarin-type anticoagulants in prolonging the prothrombin time/INR. In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs [see Drug Interactions (7.4)].
| |
| | |
| ===Proteinuria and Hematuria===
| |
| | |
| In the CRESTOR clinical trial program, dipstick-positive proteinuria and microscopic hematuria were observed among CRESTOR treated patients. These findings were more frequent in patients taking CRESTOR 40 mg, when compared to lower doses of CRESTOR or comparator HMG‑CoA reductase inhibitors, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, a dose reduction should be considered for patients on CRESTOR therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing.
| |
| | |
| ===Endocrine Effects===
| |
| | |
| Increases in HbA1c and fasting serum glucose levels have been reported with HMG‑CoA reductase inhibitors, including CRESTOR. Based on clinical trial data with CRESTOR, in some instances these increases may exceed the threshold for the diagnosis of [[diabetes mellitus]] [see Adverse Reactions (6.1)].
| |
| | |
| Although clinical studies have shown that CRESTOR alone does not reduce basal plasma cortisol concentration or impair adrenal reserve, caution should be exercised if CRESTOR is administered concomitantly with drugs that may decrease the levels or activity of endogenous [[steroid]] hormones such as [[ketoconazole]], [[spironolactone]], and [[cimetidine]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CRESTOR (ROSUVASTATIN CALCIUM) TABLET, FILM COATED [ASTRAZENECA PHARMACEUTICALS LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb0f3b5e-4bc6-41c9-66b9-6257e2513512 | publisher = | date = | accessdate = 17 February 2014 }}</ref></div>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Statins}}
| |
| | |
| [[Category:Statins]] | |
| [[Category:AstraZeneca]] | |
| [[Category:Carboxylic acids]] | |
| [[Category:Sulfonamides]]
| |
| [[Category:Pyrimidines]]
| |
| [[Category:Organofluorides]]
| |